Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
TINDAMAX (tinidazole) is an oral antiprotozoal and antimicrobial agent approved in 2004 for treating parasitic and bacterial infections. It is a nitroimidazole derivative that works by disrupting DNA synthesis in susceptible organisms. The drug is indicated for infections caused by protozoa and anaerobic bacteria.
Approaching loss of exclusivity with moderate competitive pressure (30%) signals potential team downsizing or transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"
Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study
NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)
Treatment of Bacterial Vaginosis With Oral Tinidazole
Treatment of Bacterial Vaginosis (BV) With Tinidazole
Worked on TINDAMAX at Mission Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
No jobs currently linked to TINDAMAX in available databases, reflecting the product's mature lifecycle stage and approaching LOE. Career growth on this brand is limited; professionals should expect maintenance-focused roles rather than expansion opportunities.